XBIT

XBiotech (XBIT)

XBiotech Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XBIT

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2025/01/01	05 : 22	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XBIT	XBiotech Inc
2024/12/23	23 : 00	GlobeNewswire Inc.	XBiotech Pauses Rheumatology program	NASDAQ:XBIT	XBiotech Inc
2024/11/14	05 : 12	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XBIT	XBiotech Inc
2024/08/13	03 : 38	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XBIT	XBiotech Inc
2024/06/21	01 : 57	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XBIT	XBiotech Inc
2024/06/19	00 : 35	GlobeNewswire Inc.	XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer	NASDAQ:XBIT	XBiotech Inc
2024/05/11	00 : 27	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XBIT	XBiotech Inc
2024/02/08	02 : 36	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:XBIT	XBiotech Inc
2024/02/08	02 : 01	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:XBIT	XBiotech Inc
2024/01/06	00 : 48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XBIT	XBiotech Inc
2024/01/04	23 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XBIT	XBiotech Inc
2024/01/04	23 : 00	GlobeNewswire Inc.	XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus	NASDAQ:XBIT	XBiotech Inc
2024/01/04	23 : 00	GlobeNewswire Inc.	XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus	NASDAQ:XBIT	XBiotech Inc
2023/11/14	23 : 00	GlobeNewswire Inc.	Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis	NASDAQ:XBIT	XBiotech Inc
2023/11/10	04 : 41	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XBIT	XBiotech Inc
2023/09/26	22 : 00	GlobeNewswire Inc.	XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke	NASDAQ:XBIT	XBiotech Inc
2023/08/30	22 : 00	GlobeNewswire Inc.	XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer	NASDAQ:XBIT	XBiotech Inc
2023/08/12	00 : 18	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XBIT	XBiotech Inc
2023/08/09	00 : 47	GlobeNewswire Inc.	XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial	NASDAQ:XBIT	XBiotech Inc
2023/06/26	21 : 48	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XBIT	XBiotech Inc
2023/06/26	21 : 46	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XBIT	XBiotech Inc
2023/06/26	21 : 43	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XBIT	XBiotech Inc
2023/06/26	21 : 40	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:XBIT	XBiotech Inc
2023/06/24	04 : 04	Edgar (US Regulatory)	Current Report Filing (8-k)	NASDAQ:XBIT	XBiotech Inc
2023/06/20	22 : 20	Edgar (US Regulatory)	Amended Tender Offer Statement by Issuer (sc To-i/a)	NASDAQ:XBIT	XBiotech Inc
2023/05/22	22 : 00	GlobeNewswire Inc.	FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients	NASDAQ:XBIT	XBiotech Inc
2023/05/17	22 : 22	Edgar (US Regulatory)	Tender Offer Statement by Issuer (sc To-i)	NASDAQ:XBIT	XBiotech Inc
2023/05/17	22 : 00	GlobeNewswire Inc.	XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares	NASDAQ:XBIT	XBiotech Inc
2023/05/11	04 : 42	Edgar (US Regulatory)	Quarterly Report (10-q)	NASDAQ:XBIT	XBiotech Inc
2023/04/29	01 : 38	Edgar (US Regulatory)	Annual Report to Security Holders (ars)	NASDAQ:XBIT	XBiotech Inc